IRD
Opus Genetics, Inc.NASDAQHealthcare$4.55-2.99%ClosedMarket Cap: $323.7M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
184.46
P/S
22.80
EV/EBITDA
-6.26
DCF Value
$-0.34
FCF Yield
-10.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
57.4%
Operating Margin
-271.9%
Net Margin
-349.3%
ROE
-452.3%
ROA
-98.7%
ROIC
-90.9%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $3.9M | 99.7% | $-11.5M | $-16.5M | $-0.19 | — |
| FY 2025 | $14.2M | 99.6% | $-38.6M | $-49.6M | $-0.80 | — |
| Q3 2025 | $3.1M | 99.6% | $-8.3M | $-17.5M | $-0.25 | — |
| Q2 2025 | $2.9M | -109.0% | $-8.9M | $-7.4M | $-0.12 | — |
| Q1 2025 | $4.4M | 100.0% | $-9.9M | $-8.2M | $-0.24 | — |
| Q4 2024 | $4.3M | -80.8% | $-38.0M | $-35.1M | $-1.11 | — |
| FY 2024 | $11.0M | 100.0% | $-62.1M | $-57.5M | $-2.15 | — |
| Q3 2024 | $3.9M | 100.0% | $-8.0M | $-7.5M | $-0.29 | — |
| Q2 2024 | $1.1M | 100.0% | $-8.3M | $-7.8M | $-0.30 | — |
| Q1 2024 | $1.7M | 100.0% | $-7.7M | $-7.1M | $-0.29 | — |
| Q4 2023 | $1.7M | -177.8% | $-5.4M | $-4.8M | $-0.22 | — |
| FY 2023 | $19.0M | 100.0% | $-10.6M | $-10.0M | $-0.46 | — |